Clinical and biological aspects of Multiple Myeloma
Hovenga, Sjoerd

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2007

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
References

2. Jaffe ES, Harris NL, Stein H *et al.* **Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.** 2001;


56. Derenne S, Monia B, Dean NM et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-9.


60. Quintanilla-Martinez L, Kremer M, Specht K et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. American Journal of Pathology 2003;162:1449-61.


65. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.


References


77. Tian E. Elevated expression of WNT signaling antagonists DKK1 and FrzB by malignant plasma cells is strongly associated with lytic bone disease in myeloma. The Hematology Journal 2003;S19.


99. Richardson PG. A multi-center randomized phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 2002;100:104a (abstract).


References

125. Zangari M, Barlogie B, Burns MJ et al. Velcade (V) - thalidomide (T) -
dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-
term follow-up of phase I-II Trial UARK 2001-37: superior outcome in patients
with normal cytogenetics and no prior T. 2006; Proceedings of the 47th Annual
associated with multiple myeloma.
127. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in
the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma:
128. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of
129. Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin
in transfusion-dependent anemic patients with multiple myeloma and
non-Hodgkin’s lymphoma-a randomized multicenter study. The European Study
Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and
130. Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis
skeletal events in patients with advanced multiple myeloma. Myeloma Aredia
133. McCloskey EV, MacLennan IC, Drayson MT et al. A randomized trial of the effect
of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party
ibandronate therapy on skeletal-related events, survival, and bone resorption
markers in patients with advanced multiple myeloma.
acid stimulate osteoprotegerin production by primary human osteoblasts.
147. Vellenga E, de Wolf JThM, Beentjes JAM *et al.* **Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells.** Blood 1990;75:633-7.
References


References


193. Oakervee HE, McBride NC, Hemmaway CJ. Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. Blood 2002;100:402A.


197. Chung F, Palmer BD, Muller GW et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncology Research 2003;14:75-82.


References


References


References


